Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (9888)	5/10/1999 10:15:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

In your post you had>>>>>>>>>the composite " The proportion of patients who developed either pneumonia or ARDS was 32% in the placebo group vs 22% in the rBPI21 group post hoc p = 0.03"<<<<<<<<<<< Now I would have to see and analyze cost savings of patient not getting ARDS and to lesser extent pneumonia. As you say hopefully luck is with us and we can do even better in phase III. Remember we snagged this post hoc and thank goodness we did because mortality was too low overall. And it may boil down to maybe squeaking by on Meningo. and maybe become greatest drug used off label known to man!<g>